Oruka Therapeutics Inc D
D
ORKA
80.190
USD
-0.92
(-1.13%)
Market Closed
Last updated: · Delayed 15 min
Volume
16,652
EPS
-2
Div Yield
-
P/E
-39
Market Cap
5,309,355,763
Title: Oruka Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and otherconditions.